Clinical Trial

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-17
Trial Details
NCT Number NCT07654972
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight
Enrollment 108 participants
Start Date 2026-06-24
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-16